MedPharm has appointed Bill Humphries as its new CEO, marking a significant step in the company's strategic growth.

The move follows the company’s merger with Great Point Partners portfolio company, Tergus Pharma, in July 2024, enhancing its clinical trial manufacturing, commercial production capabilities and scientific expertise.

With more than 36 years of experience in leadership and business transformation in the life sciences and pharmaceutical industries, Humphries is poised to lead the company into its next phase of development.

His background includes roles as CEO of Alcami, where he led operational improvements, client satisfaction and revenue growth, CEO of Isosceles Pharmaceuticals and CEO of Merz North America.

Humphries has also held significant roles at Ortho-Dermatologics, Stiefel and Allergan Pharmaceuticals.

He also served as Clearside Biomedical’s board chairman, STRATA Skin Sciences’ executive chairman, and as a board member for Aclaris Therapeutics, Alcami, PhaseBio Pharmaceuticals, Bryn Pharmaceuticals and SKNV.

Humphries said: "It is a privilege to join MedPharm and the team at this important period in [its] evolution and growth aspirations.

"I am excited to be part of this team and leverage my direct experience in the topical and transdermal space to accelerate MedPharm's growth. I believe MedPharm is well positioned to serve clients across all channels in the topical space, and we look forward to delivering incremental value for trusted existing and new clients."

MedPharm offers a range of end-to-end contract services for transepithelial and topical products. This includes early-phase research, in vitro testing services, clinical and commercial manufacturing and formulation development.

The company is backed by investors Bourne Partners Strategic Capital, Great Point Partners and Ampersand Capital Partners.

It has facilities in both the US and the UK, including a new 97,000ft² manufacturing facility in Durham, North Carolina, US.